Sodium iodide symporter for nuclear molecular imaging and gene ther-apy: From bedside to bench and back

Theranostics

Volumn 2, Issue 4, 2012, Pages 392-402

  Ahn, Byeong Cheol ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

Gene therapy; Molecular imaging; Radionuclide; Radionuclide based imaging; Sodium iodide symporter

Indexed keywords

ASTATINE 211; FLUORINE 18; IODINE 123; IODINE 124; IODINE 131; MEMBRANE PROTEIN; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; RHENIUM 188; SODIUM IODIDE SYMPORTER; TECHNETIUM 99M; TELLURIUM 123; UNCLASSIFIED DRUG; XENON 124;

CELL MIGRATION; CYTOSOL; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIATED THYROID CANCER; EXTRACELLULAR FLUID; GENE THERAPY; GENE TRANSFER; HUMAN; MOLECULAR IMAGING; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; REPORTER GENE; REVIEW;

EID: 84864538409     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.3722     Document Type: Review

References (53)

1. Riesco-Eizaguirre G, Santisteban P. A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol. 2006; 155: 495-512.
2. Soto GD, Halperin I, Squarcia M, Lomena F, Domingo MP. Update in thyroid imaging. The expanding world of thyroid imaging and its translation to clinical practice. Hormones (Athens). 2010; 9: 287-98.
3. Verburg FA, de Keizer B, van Isselt JW. Use of radiopharmaceuticals for diagnosis, treatment, and follow-up of differentiated thyroid carcinoma. Anticancer Agents Med Chem. 2007; 7: 399-409.
4. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature. 1996; 379: 458-60.
5. Msaouel P, Dispenzieri A, Galanis E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther. 2009; 11: 43-53.
6. Barton KN, Stricker H, Brown SL, Elshaikh M, Aref I, Lu M, et al. Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther. 2008; 16: 1761-9.
7. Seo JH, Jeon YH, Lee YJ, Yoon GS, Won DI, Ha JH, et al. Trafficking macrophage migration using reporter gene imaging with human sodium iodide symporter in animal models of inflammation. J Nucl Med. 2010; 51: 1637-43.
8. Ahn SJ, Jeon YH, Lee YJ, Lee YL, Lee SW, Ahn BC, et al. Enhanced anti-tumor effects of combined MDR1 RNA interference and human sodium/iodide symporter (NIS) radioiodine gene therapy using an adenoviral system in a colon cancer model. Cancer Gene Ther. 2010; 17: 492-500.
9. Jeon YH, Ahn SJ, Lee YJ, Lee YL, Lee SW, Park SY, et al. Human sodium iodide symporter added to multidrug resistance 1 small hairpin RNA in a single gene construct enhances the therapeutic effects of radioiodine in a nude mouse model of multidrug resistant colon cancer. Cancer Biother Radiopharm. 2011; 25: 671-9.
10. Lee YL, Lee YJ, Ahn SJ, Choi TH, Moon BS, Cheon GJ, et al. Combined radionuclide-chemotherapy and in vivo imaging of hepatocellular carcinoma cells after transfection of a triple-gene construct, NIS, HSV1-sr39tk, and EGFP. Cancer Lett. 2010; 290: 129-38.
11. Spitzweg C, Harrington KJ, Pinke LA, Vile RG, Morris JC. Clinical review 132: The sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab. 2001; 86: 3327-35.
12. Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, et al. The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev. 2003; 24: 48-77.
13. Hingorani M, Spitzweg C, Vassaux G, Newbold K, Melcher A, Pandha H, et al. The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr Cancer Drug Targets. 2010; 10: 242-67.
14. Wapnir IL, van de Rijn M, Nowels K, Amenta PS, Walton K, Montgomery K, et al. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab. 2003; 88: 1880-8.
15. Baril P, Martin-Duque P, Vassaux G. Visualization of gene expression in the live subject using the Na/I symporter as a reporter gene: applications in biotherapy. Br J Pharmacol. 2010; 159: 761-71.
16. Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med. 2002; 43: 1188-200.
17. Jeong SY, Hwang MH, Kim JE, Kang S, Park JC, Yoo J, et al. Combined Cerenkov luminescence and nuclear imaging of radioiodine in the thyroid gland and thyroid cancer cells expressing sodium iodide symporter: initial feasibility study. Endocr J. 2011; 58: 575-83.
18. Silberstein EB, Alavi A, Balon HR, Becker DV, Brill DR, Clarke SEM, et al. Society of Nuclear Medicine Procedure Guideline for Therapy of Thyroid Disease with Iodine-131 (Sodium Iodide) Version 2.0. Society of Nuclear Medicine. 2005.
19. Rault E, Vandenberghe S, Van Holen R, De Beenhouwer J, Staelens S, Lemahieu I. Comparison of image quality of different iodine isotopes (I-123, I-124, and I-131). Cancer Biother Radiopharm. 2007; 22: 423-30.
20. Jauregui-Osoro M, Sunassee K, Weeks AJ, Berry DJ, Paul RL, Cleij M, et al. Synthesis and biological evaluation of [(18)F]tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporter. Eur J Nucl Med Mol Imaging. 2010; 37: 2108-16.
21. Lindencrona U, Forssell-Aronsson E, Nilsson M. Transport of free 211At and 125I- in thyroid epithelial cells: effects of anion channel blocker 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid on apical efflux and cellular retention. Nucl Med Biol. 2007; 34: 523-30.
22. Frier M. Rhenium-188 and copper-67 radiopharmaceuticals for the treatment of bladder cancer. Mini Rev Med Chem. 2004; 4: 61-8.
23. Jansen DR, Krijger GC, Kolar ZI, Zonnenberg BA, Zeevaart JR. Targeted radiotherapy of bone malignancies. Curr Drug Discov Technol. 2010; 7: 233-46.
24. Imam SK. Advancements in cancer therapy with alpha-emitters: a review. Int J Radiat Oncol Biol Phys. 2001; 51: 271-8.
25. Ahn BC, Lee SW, Lee J, Kim C. Pulmonary aspergilloma mimicking metastasis from papillary thyroid cancer. Thyroid. 2011; 21: 555-8.
26. Johnson NA, LeBeau SO, Tublin ME. Imaging surveillance of differentiated thyroid cancer. Radiol Clin North Am. 2011; 49: 473-87.
27. Wong KK, Zarzhevsky N, Cahill JM, Frey KA, Avram AM. Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma. Br J Radiol. 2009; 82: 860-76.
28. Ahn BC. Applications of molecular imaging in drug discovery and development process. Curr Pharm Biotechnol. 2011; 12: 459-68.
29. Pichler BJ, Wehrl HF, Judenhofer MS. Latest advances in molecular imaging instrumentation. J Nucl Med. 2008; 49 Suppl 2: 5S-23S.
30. Shim HK, Kim SG, Kim TS, Kim SK, Lee SJ. Total thyroidectomy in the mouse: the feasibility study in the non-thyroidal tumor model expressing human sodium/Iodide symporter gene. Nucl Med Mol Imag. 2011; 45: 103-10.
31. Verburg FA, Brans B, Mottaghy F. Molecular nuclear therapies for thyroid carcinoma. Methods. 2011.
32. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001; 86: 1447-63.
33. Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. J Am Med Assoc. 1946; 132: 838-47.
34. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19: 1167-214.
35. Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011; 21: 593-646.
36. Oh SW, Moon SH, Park do J, Cho BY, Jung KC, Lee DS, et al. Combined therapy with (131)I and retinoic acid in Korean patients with radioiodine-refractory papillary thyroid cancer. Eur J Nucl Med Mol Imaging. 2011; 38: 1798-805.
37. Wu SY, Kollin J, Coodley E, Lockyer T, Lyons KP, Moran E, et al. I-131 total-body scan: localization of disseminated gastric adenocarcinoma. Case report and survey of the literature. J Nucl Med. 1984; 25: 1204-9.
38. Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med. 2000; 6: 871-8.
39. Spitzweg C, Morris JC. The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol (Oxf). 2002; 57: 559-74.
40. Moon DH, Lee SJ, Park KY, Park KK, Ahn SH, Pai MS, et al. Correlation between 99mTc-pertechnetate uptakes and expressions of human sodium iodide symporter gene in breast tumor tissues. Nucl Med Biol. 2001; 28: 829-34.
41. Willhauck MJ, DJ OK, Wunderlich N, Goke B, Spitzweg C. Stimulation of retinoic acid-induced functional sodium iodide symporter (NIS) expression and cytotoxicity of (1)(3)(1)I by carbamazepine in breast cancer cells. Breast Cancer Res Treat. 2011; 125: 377-86.
42. Mu D, Huang R, Ma X, Li S, Kuang A. Radioiodine therapy of thyroid carcinoma following Pax-8 gene transfer. Gene Ther. 2011; doi:gt2011110 [pii] 10.1038/gt.2011.110.
43. Altmann A, Schulz RB, Glensch G, Eskerski H, Zitzmann S, Eisenhut M, et al. Effects of Pax8 and TTF-1 thyroid transcription factor gene transfer in hepatoma cells: imaging of functional protein-protein interaction and iodide uptake. J Nucl Med. 2005; 46: 831-9.
44. Lee YJ, Chung JK, Kang JH, Jeong JM, Lee DS, Lee MC. Wild-type p53 enhances the cytotoxic effect of radionuclide gene therapy using sodium iodide symporter in a murine anaplastic thyroid cancer model. Eur J Nucl Med Mol Imaging. 2010; 37: 235-41.
45. Lindencrona U, Nilsson M, Forssell-Aronsson E. Similarities and differences between free 211At and 125I- transport in porcine thyroid epithelial cells cultured in bicameral chambers. Nucl Med Biol. 2001; 28: 41-50.
46. Petrich T, Quintanilla-Martinez L, Korkmaz Z, Samson E, Helmeke HJ, Meyer GJ, et al. Effective cancer therapy with the alpha-particle emitter [211At]astatine in a mouse model of genetically modified sodium/iodide symporter-expressing tumors. Clin Cancer Res. 2006; 12: 1342-8.
47. Kim J, Ahn BC, Hwang MH, Lee HW, Jeon YH, Jeong SY, et al. Combined RNA Interference of Hexokinase II and I-131 human Sodium Iodide Symporter Gene Therapy in Anaplastic Thyroid Carcinoma. J Nucl Med. 2011; 52: 1756-63.
48. Scanlon KJ. Cancer gene therapy: challenges and opportunities. Anticancer Res. 2004; 24: 501-4.
49. Spitzweg C, Scholz IV, Bergert ER, Tindall DJ, Young CY, Goke B, et al. Retinoic acid-induced stimulation of sodium iodide symporter expression and cytotoxicity of radioiodine in prostate cancer cells. Endocrinology. 2003; 144: 3423-32.
50. Harrington KJ, Melcher A, Vassaux G, Pandha HS, Vile RG. Exploiting synergies between radiation and oncolytic viruses. Curr Opin Mol Ther. 2008; 10: 362-70.
51. Hingorani M, White CL, Zaidi S, Pandha HS, Melcher AA, Bhide SA, et al. Therapeutic effect of sodium iodide symporter gene therapy combined with external beam radiotherapy and targeted drugs that inhibit DNA repair. Mol Ther. 2010; 18: 1599-605.
52. Wapnir IL, Goris M, Yudd A, Dohan O, Adelman D, Nowels K, et al. The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid. Clin Cancer Res. 2004; 10: 4294-302.
53. Kim HW, Ahn BC, Lee SW, Lee J. Effect of Parotid Gland Mas-sage on Parotid Gland Tc-99m pertechnetate Uptake. Thyroid. 2012; doi:10.1089/thy.2011-0188.